









市場行情
/
股票
/
nasdaq-sln
/

Silence Therapeutics PLC

SLN

6.450USD

+0.080+1.26%

收盤 12/22, 16:00（美東）報價延遲15分鐘

304.66M總市值

虧損本益比TTM



Silence Therapeutics PLC

6.450

+0.080+1.26%

概覽公司財務分析

概覽

公司

財務

分析

關於 Silence Therapeutics PLC 公司

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Silence Therapeutics PLC簡介



公司代碼SLN

公司名稱Silence Therapeutics PLC

上市日期Jan 05, 2010

CEOTooman (Craig A)

員工數量116

證券類型Depository Receipt

年結日Jan 05

公司地址72 Hammersmith Road

城市LONDON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編W14 8TH

電話442034576900

網址https://www.silence-therapeutics.com/

公司代碼SLN

上市日期Jan 05, 2010

CEOTooman (Craig A)

Silence Therapeutics PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Timothy (Tim) McInerney

Independent Director

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

Ms. Gem Hopkins

Head of IR and Corporate Communications

名稱

名稱/職務

職務

持股

持股變動

Mr. Timothy (Tim) McInerney

Independent Director

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United Kingdom

43.11M

99.67%

Germany

144.00K

0.33%

USA

0.00

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

6.16%

Redmile Group, LLC

4.58%

Lombard Odier Asset Management (USA) Corp.

3.91%

其他

54.55%

持股股東

佔比

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

6.16%

Redmile Group, LLC

4.58%

Lombard Odier Asset Management (USA) Corp.

3.91%

其他

54.55%

股東類型

持股股東

佔比

Individual Investor

24.38%

Investment Advisor

18.46%

Investment Advisor/Hedge Fund

9.97%

Venture Capital

3.35%

Hedge Fund

3.30%

Research Firm

3.11%

Private Equity

2.05%

Bank and Trust

0.03%

其他

35.34%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

138

19.95M

42.23%

-14.76M

2025Q2

131

33.68M

71.31%

-14.18M

2025Q1

133

31.94M

67.63%

-14.00M

2024Q4

128

31.43M

66.56%

-10.23M

2024Q3

111

35.93M

77.05%

-5.19M

2024Q2

34.94M

74.95%

-4.57M

2024Q1

35.43M

76.18%

+4.14M

2023Q4

30.21M

78.15%

-609.51K

2023Q3

32.62M

88.08%

+1.55M

2023Q2

31.78M

89.08%

+2.79M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Griffiths (Richard Ian)

11.51M

24.38%

+543.58K

+4.95%

Jun 25, 2025

TCG Crossover Management, LLC

3.03M

6.42%

Jun 30, 2025

Invus Public Equities Advisors, LLC

2.91M

6.16%

+121.61K

+4.36%

Jun 30, 2025

Redmile Group, LLC

2.16M

4.58%

-50.17K

-2.27%

Jun 30, 2025

Lombard Odier Asset Management (USA) Corp.

1.85M

3.92%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.13M

2.39%

-766.91K

-40.44%

Jun 30, 2025

Vivo Capital, LLC

1.11M

2.34%

Jun 30, 2025

Nantahala Capital Management, LLC

1.04M

2.21%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

970.13K

2.05%

-178.46K

-15.54%

Jun 30, 2025

Nextech Invest, Ltd.

952.40K

2.02%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

0.87%

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

SPDR S&P International Small Cap ETF

0.01%

ActivePassive International Equity ETF

iShares Biotechnology ETF

Tema Heart & Health ETF

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.87%

ProShares Ultra Nasdaq Biotechnology

佔比0.03%

Invesco Nasdaq Biotechnology ETF

佔比0.03%

SPDR S&P International Small Cap ETF

佔比0.01%

ActivePassive International Equity ETF

佔比0%

iShares Biotechnology ETF

佔比0%

Tema Heart & Health ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Silence Therapeutics PLC的前五大股東是誰？



Silence Therapeutics PLC的前五大股東如下：
Griffiths (Richard Ian)
持有股份：11.51M
佔總股份比例：24.38%。
TCG Crossover Management, LLC
持有股份：3.03M
佔總股份比例：6.42%。
Invus Public Equities Advisors, LLC
持有股份：2.91M
佔總股份比例：6.16%。
Redmile Group, LLC
持有股份：2.16M
佔總股份比例：4.58%。
Lombard Odier Asset Management (USA) Corp.
持有股份：1.85M
佔總股份比例：3.92%。